Hims & Hers: AI-Powered Healthcare Disruption
Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase. See why I rate HIMS stock a ...
pharmaphorum22h
Novo Nordisk’s oral amycretin tops Wegovy in obesity trial
Novo Nordisk’s already buoyant share price rose ... Neurotech's cell therapy gets FDA nod for eye disorder MacTe... Neurotech Pharma's cell therapy Encelto has become the first FDA-approved ...
Generic drugmaker races to launch versions of blockbuster obesity drugs
Pharma group Hikma looks to take advantage as Novo Nordisk’s Wegovy and Ozempic start to go off patent next year ...
Hikma races to launch generic versions of blockbuster obesity drugs
Hikma launched liraglutide, a generic version of an earlier Novo Nordisk weight loss drug, in the US in December. Liraglutide, which Novo sells as Victoza for diabetes and Saxenda for weight loss, has ...
pharmaphorum22h
Novo Nordisk forges close ties with biotech VC Flagship
The partnership with Flagship will bring Novo Nordisk into closer contact with the VC's portfolio of 41 biotech companies, with the aim of creating a portfolio of "transformational" medicines for ...